Behavioral response profiles following drug challenge with dopamine receptor subtype agonists and antagonists in developing rat

Neurotoxicology and Teratology

Volumn 25, Issue 3, 2003, Pages 311-328

  Sobrian, Sonya K ^a   Jones, Barbara L ^a   Varghese, Shiny ^a   Holson, R Robert ^b  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NEW MEXICO INSTITUTE OF MINING AND TECHNOLOGY   (United States)

Author keywords

7 OH DPAT; Apomorphine; Dopamine receptor subtypes; Drug challenge; Nafadotride; Ontogeny; PD 152255; Quinpirole; SCH 23390; SKF 38393; Spiroperidol

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALCOHOL; APOMORPHINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; NAFADOTRIDE; PD 152255; QUINPIROLE; SODIUM CHLORIDE; SPIPERONE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BITE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; GROOMING; HEAD MOVEMENT; LICKING; MALE; MASTICATION; NEWBORN; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RAT; REARING; SNIFFING; YAWNING;

POROMITRA OSCITANS;

EID: 0037903568     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(03)00009-6     Document Type: Article

References (117)

1. Adachi K., Ikeda H., Hasegawa M., Nakamura S., Waddington J.L., Koshikawa N. SK&F 83959 and non-cyclase-coupled dopamine D-1-like receptors in jaw movements via dopamine D-1-like/D-2-like receptor synergism. Eur. J. Pharmacol. 367:1999;143-149.
2. Ahlenius S., Salmi P. Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur. J. Pharmacol. 260:1994;177-181.
3. Altman J., Bayer S.A. Development of the Cerebellar System. 1997;324-333 CRC Press, Boca Raton, FL.
4. Anderson S.L., Gazzara R.A. The ontogeny of apomorphine-induced alterations of neostriatal dopamine release: effects on spontaneous release. J. Neurochem. 61:1993;2247-2255.
5. Arnt J. Differential behavioural effects of dopamine agonists in developing rats: a study of 3-PPP enantiomers. Eur. J. Pharmacol. 91:1983;273-278.
6. Arnt J., Hyttel J., Perregaard J. Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behavior in rats. Eur. J. Pharmacol. 133:1987;137-145.
7. Baez L.A., Burt D.K., Granneman J., Shanklin C. Dopaminergic antagonism and catalepsy in the developing rats. Eur. J. Pharmacol. 54:1979;15-20.
8. Baez L.A., Eskridge N.K., Schein R. Postnatal development of dopaminergic and cholinergic catalepsy in the rat. Eur. J. Pharmacol. 36:1976;155-162.
9. Baldessarini R.J., Tarazi F.I. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv. Rev. Psychiatr. 3:1996;301-325.
10. Beninger R.J., Mazurski E.J., Hoffman D.C. Receptor subtype-specific dopaminergic agents and unconditioned behavior. Pol. J. Pharmacol. Pharm. 43:1991;507-528.
11. Boulay D., Depoortere R., Rostene W., Perrault G., Sanger D.J. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology. 38:1999;555-565.
12. Boyson S.K., McGonigle P., Molinoff P.B. Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6:1986;3177-3188.
13. Braun A.R., Chase T.N. Obligatory D1/D2 receptor interaction in the generation of dopamine agonist related behavior. Eur. J. Pharmacol. 131:1986;301-306.
14. Caboche J., Rogard M., Besson M.J. Comparative development of D1-dopamine and mu-opiate receptors in normal and in 6-hydroxydopamine-lesioned neonatal rat striatum: dopaminergic fibers regulate mu but not D1-receptor distribution. Dev. Brain Res. 58:1991;111-122.
15. Caine S.B., Koob G.F. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science. 260:1993;1814-1816.
16. Carlsson S.G. Effects of apomorphine on exploration. Physiol. Behav. 9:1972;127-129.
17. Cervo L., Samanin R. Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats. Brain Res. 731:1996;31-38.
18. Chow H.L., Beck H.L. The effects of apomorphine on the open-field behavior of rats: alone and in pairs. Pharmacol. Biochem. Behav. 21:1984;85-88.
19. Christian A.J., Goodwin A.K., Baker L.E. Antagonism of the discriminative stimulus effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A. Pharmacol. Biochem. Behav. 68:2001;371-377.
20. Clifford J.J., Waddington J.L. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach. Psychopharmacology. 136:1998;284-290.
21. Collins P., Broekkamp C.L.E., Jenner P., Marsden C.D. Drugs acting at D-1 and D-2 dopamine-receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology. 103:1991;503-512.
22. Corbin A.E., Pugsley T.A., Akunne H.C., Whetzel S.Z., Zoski K.T., Georgic L.M., Nelson C.B., Wright J.L., Wise L.D., Heffner T.G. Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist. Pharmacol. Biochem. Behav. 59:1998;487-493.
23. Daly S.A., Waddington J.L. Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2 like" agonists. Neuropharmacology. 32:1993;509-510.
24. DeBoer P., Enrico P., Wright J., Wise L.D., Timmerman W., Moor E., Dijkstra D., Wikstrom H.V., Westerink B.H. Characterization of the effect of dopamine D3 receptor stimulation on locomotion and striatal dopamine levels. Brain Res. 758:1997;83-91.
25. Depoortere R., Perrault G., Sanger D.J. Behavioral effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology. 124:1996;231-240.
26. Deveney A.M., Waddington J.L. Pharmacological characterization of behavioral responses to SK&F 83959 in relation to "D-1 like" dopamine receptors not linked to adenyl cyclase. Br. J. Pharmacol. 116:1995;2120-2126.
27. Deveney A.M., Waddington J.L. Psychopharmacological distinction between novel full-efficacy "D-1 like" dopamine receptor agonists. Pharmacol. Biochem. Behav. 58:1997;551-558.
28. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 20:2000;8677-8684.
29. Dziedzicka-Wasylewske M., Rogoz Z. Time-dependent effects of antidepressant drugs on the low dose of apomorphine-induced locomotor hypoactivity in rats. Pol. J. Pharmacol. 49:1997;337-343.
30. Eilam D., Clements K.V., Szechtman H. Differential effects of D1 and D2 dopamine agonists on stereotyped locomotion in rats. Behav. Brain Res. 45:1991;117-124.
31. Eilam D., Szechtman H. Biphasic effects of D-2 agonist quinpirole on locomotion and movements. Eur. J. Pharmacol. 161:1989;151-157.
32. Eilam D., Szechtman H., Spear L.P. Quinpirole alters quadruped activity in rats from the second postnatal week. Dev. Psychobiol. 25:1992;275-289.
33. Eilam D., Talangbayan H., Canaran G., Szechtman H. Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors. Psychopharmacology. 106:1992;447-454.
34. Ellison G., Johansson P., Levin E., See R., Gunne L. Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and D2 agonist LY171555 on oral movements in rats. Psychopharmacology. 96:1988;252-257.
35. Ferrari F., Giuliani D. Influence of idazoxan on the dopamine D2 receptor agonist-induced behavioral effects in rats. Eur. J. Pharmacol. 250:1993;51-57.
36. Fitzgerald L.W., Hannigan J.H. Cholinergic maturation and SCH-23390-induced catalepsy in the male rat pup. Dev. Brain Res. 47:1989;147-150.
37. Fliestar R.J., Levant B. Comparison of D2 and D3 dopamine receptor affinity of dopaminergic compounds in rat brain. Life Sci. 62:1998;1825-1831.
38. Frantz K.J., Van Hartesveldt C. The locomotor effects of quinpirole in rats depend on age and gender. Pharmacol. Biochem. Behav. 64:1999;821-826.
39. Fray P.J., Sahakian B.J., Robbins T.W., Koob G.F., Iversen S.D. An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of D-amphetamine and apomorphine. Psychopharmacology (Berl.). 69:1980;253-259.
40. Gazzara R.A., Andersen S.L. The ontogeny of apomorphine-induced alterations of neostriatal dopamine release: effects on potassium-evoked release. Neurochem. Res. 19:1993;339-345.
41. Gelbard H.A., Teicher M.H., Faedda G., Baldessarini R.J. Postnatal development of dopamine D1 and D2 receptor sites in striatum. Dev. Brain Res. 49:1989;123-130.
42. Geter-Douglas B., Katz J.L., Alling K., Acri J.B., Witkins J.M. Characterization of unconditioned behavioral effects of dopamine D3/D2 agonists. J. Pharmacol. Exp. Ther. 283:1997;7-15.
43. Gingrich J.A., Caron M.G. Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16:1993;299-321.
44. Giorgi O., DeMontis G., Porceddu M.L., Mele S., Calderini G., Toffano G., Biggio G. Developmental and age-related changes in D1-dopamine receptors and dopamine content in the rat striatum. Dev. Brain Res. 35:1987;283-290.
45. Gordon D., Beck C.H. Subacute apomorphine injections in rats: effects on components of behavioral stereotypy. Behav. Neural Biol. 41:1984;200-208.
46. Goudie A.J., Baker L.E., Smith J.A., Prus A.J., Svensson K.A., Cortes-Burgos L.A., Wong E.H.F., Haadsma-Svensson S. Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D3 preferring antagonist PNU-99194A: an analysis of possible mechanisms. Behav. Pharmacol. 12:2001;303-315.
47. Hedner T., Lundborg P. Development of dopamine autoreceptors in the postnatal rat brain. J. Neural Transm. 62:1985;53-63.
48. Heijtz R.D., Ogren S.O., Fuxe K. Ontogeny of the motor inhibitory role of dopamine D(3) receptor subtype in rats. Eur. J. Pharmacol. 392:2000;35-39.
49. Isaacson R.L., Younge B., Clearu D.M. Dopamine agonists - Their effect on locomotion and exploration. Behav. Biol. 23:1978;163-179.
50. Johansson P., Levin E., Gunne L., Ellison G. Opposite effects of a D-1 and D-2 agonist on oral movements in rats. Eur. J. Pharmacol. 134:1987;83-88.
51. Kebabian J.W., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
52. Khroyan T.A., Baker D.A., Neiswander J.L. Dose-dependent effects of the D3-prefering agonists 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology. 122:1995;351-357.
53. Koeltzow T.E., Xu M., Cooper D.C., Hu X., Tonegawa S., Wolf M.E., White F.J. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 18:1998;2231-2238.
54. Koshikawa N., de Beltran K.K., Tomiyama K., Kobayashi M., Cools A.R. Functional interaction between dopamine-D1 and dopamine-D2 receptors in rat jaw movements. Eur. J. Pharmacol. 201:1991;47-51.
55. Kostrzewa R.M., Brus R., Rykaczewska M., Plech A. Low dose quinpirole ontogenetically sensitizes to quinpirole-induced yawning in rats. Pharmacol. Biochem. Behav. 44:1993;487-489.
56. Kostrzewa R.M., Kastin A.J. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats. Brain Res. Bull. 31:1993;707-712.
57. Kreiss D.S., Bergstrom D.A., Gonzalez A.M., Huang K.X., Sibley D.R., Walters J.R. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur. J. Pharmacol. 277:1995;209-214.
58. Kurashima M., Yamada K., Nagashiima M., Shirakawa K., Furukawa T. Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol. Biochem. Behav. 52:1995;503-508.
59. Leslie C.A., Robertson M.W., Cutler A.J., Bennett J.P. Jr. Postnatal development of D1 dopamine receptors in the medial prefrontal cortex, striatum and nucleus accumbens of normal and neonatal 6-hydroxydopamine treated rats: a quantitative autoradiographic analysis. Brain Res. Dev. Brain Res. 62:1991;109-114.
60. Levant B., Vansell N.R. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology. 17:1997;67-71.
61. Lin M.Y., Walters D.E. The D2 autoreceptor agonists SND 919 and PD 128483 decrease stereotypy in developing rats. Life Sci. 54:1994;17-22.
62. Lin M.Y., Walters D.E. Dopamine D2 autoreceptors in rats are behaviorally functional at 21 but not 10 days of age. Psychopharmacology (Berl.). 114:1994;262-268.
63. Ljungberg T., Ungerstedt U. Different behavioural patterns induced by apomorphine: evidence that the method of administration determines the behavioural response to the drug. Eur. J. Pharmacol. 46:1977;41-50.
64. Ljungberg T., Ungerstedt U. Apomorphine-induced locomotion and gnawing: evidence that the experimental design greatly influences gnawing while locomotion remains unchanged. Eur. J. Pharmacol. 46:1977;147-151.
65. Longoni R., Spina L., Di Chiara G. Permissive role of D-1 receptor stimulation by endogenous dopamine for the expression of postsynaptic D-2-mediated behavioural responses. Yawning in rats. Eur. J. Pharmacol. 134:1987;163-173.
66. Maj J., Grabowska M., Gajda L. Effects of apomorphine on motility in rats. Eur. J. Pharmacol. 17:1972;208-214.
67. Maj J., Przewlocka J., Kukulka L. Sedative action of low doses of dopaminergic agents. Pol. J. Pharmacol. 29:1977;11-21.
68. McDevitt J.T., Setler P.E. Differential effects of dopamine agonists in mature and immature rats. Eur. J. Pharmacol. 72:1990;69-75.
69. McDougall S.A., Arnold T.F., Nonneman A.J. Ontogeny of locomotor activity in the young rat: role of dopamine D1 and D2 receptors. Eur. J. Pharmacol. 186:1990;223-230.
70. Meller E., Bordi F., Bohmaker K. Enhancement by the D1 dopamine agonist SKF 38393 of specific components of stereotypy elicited by the D2 agonists LY 171555 and RU 24213. Life Sci. 42:1988;2561-2567.
71. Meyer M.E. Mesolimbic 7-OH-DPAT affects locomotor activities in rats. Pharmacol. Biochem. Behav. 55:1996;209-214.
72. Meyer M.E., Cottrell G.A., Van Hartesveldt C., Porter T.J. Effects of dopamine D1 antagonists SCH 23390 and SK&F 83566 on locomotor activity in rats. Pharmacol. Biochem. Behav. 44:1993;429-432.
73. Meyer J.S., Kunkle R. Behavioral responses to a D-1 dopamine agonist in weanling rats treated neonatally with cocaine and delta-9-tetrahydrocannabinol. Neurotoxicol. Teratol. 21:1999;375-380.
74. Meyer M.E., Shults J.M. Dopamine D-1 receptor family agonists, SK&F 38393, SK&F 77434, and SK&F 82958, differentially affect locomotor activities in rats. Pharmacol. Biochem. Behav. 46:1993;269-274.
75. Millan M.J., Dekeyne A., Rivet J.M., Dubuffet T., Lavielle G., Brocco M. S33084, a novel, potent selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 2000;1063-1073.
76. Mjörndal T., Persson S.A. The relation between spiperone binding, behavioural changes, and in vivo tyrosine hydroxylation in the rat striatum. Naunyn-Schmiedeberg's Arch. Pharmacol. 322:1983;136-139.
77. Molino L.J., Shemer A., Whitaker-Azmitia P.M. SKF 38393: vacillatory behavior in immature rats. Eur. J. Pharmacol. 161:1989;223-225.
78. Molloy A.G., Waddington J.L. Dopaminergic behavior stereospecifically promoted by the D1 agonist R-SK&F 38398 and selectively blocked by the D1 antagonist SCH 23390. Psychopharmacology. 82:1984;409-410.
79. Molloy A.G., Waddington J.L. Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SK&F 38393 and its R- and S-enantiomers in the intact adult rat. Psychopharmacology. 92:1987;164-169.
80. Moody C.A., Frambes N.A., Spear L.P. Psychopharmacological responsiveness to the dopamine agonist quinpirole in normal weanling and in weanling offspring exposed gestationally to cocaine. Psychopharmacology. 108:1992;256-262.
81. Moody C.A., Spear L.P. Ontogenetic differences in the psychopharmacological responses to separate and combined stimulation of D1 and D2 receptors during the neonatal to weanling age period. Psychopharmacology. 106:1992;161-168.
82. Moody C.A., Spear L.P. Effects of acute dopamine depletion on responsiveness to D1 and D2 receptor agonists in infant and weanling rat pups. Psychopharmacology. 107:1992;39-49.
83. Murray A.M., Waddington J.L. The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction. Eur. J. Pharmacol. 160:1989;377-384.
84. Paulus M.P., Geyer M.A. A scaling approach to find order parameters quantifying the effects of dopaminergic agents on unconditioned motor-activity in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 15:1991;903-919.
85. Puesch A.J., Simon P., Chernat R., Bossier J.R. Profil neuropsychopharmacolique de l'apomorphine. J. Pharmacol. (Paris). 5:1974;241-254.
86. Pugsley T.A., Davis M.D., Akunne H.C., Mackenzie R.G., Shih Y.H., Damsma G., Wilkstrom H., Whetzel S.Z., Georgic L.M., Cooke L.W., Demattos S.B., Corbin A.E., Glase S.A., Wise L.D., Dijkstra D., Heffner T.G. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 275:1995;1355-1366.
87. Radhakishun F.S., Van Ree J.M. The hypomotility elicited by small doses of apomorphine seems exclusively mediated by dopaminergic systems in the nucleus accumbens. Eur. J. Pharmacol. 137:1987;41-47.
88. Rao P.A., Molinoff P.B., Joyce J.N. Ontogeny of dopamine D1 and D2 receptor subtypes in rat basal ganglia: a quantitative autoradiographic study. Dev. Brain Res. 60:1991;161-177.
89. Sautel F., Griffon N., Sokoloff P., Schwartz J.C., Launay C., Simom P., Costentin J., Schoenfelder A., Garrido F., Mann A. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 275:1995;1239-1246.
90. Schambra U.B., Duncan G.E., Breese G.R., Fornaretto M.G., Caron M.G., Fremeau R.T. Jr. Ontogeny of D1A and D2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding. Neuroscience. 62:1994;65-85.
91. Schwartz J.C., Griffon N., Diaz J., Levesque D., Sautel F., Sokoloff P., Simon P., Costentin J., Garrido F., Mann A. The D3 receptor and its relevance in psychiatry. Int. Clin. Psychopharmacol. Suppl. 3:1995;15-20.
92. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15:1994;264-270.
93. Shalaby I.A., Spear L.P. Psychopharmacological effects of low and high doses of apomorphine during ontogeny. Eur. J. Pharmacol. 67:1980;451-459.
94. Shieh G.J., Walters D.E. Stimulating dopamine D-1 receptors increases the locomotor activity of developing rats. Eur. J. Pharmacol. 311:1996;103-107.
95. Sobrian S.K., Ali S.F., Slikker W. Jr., Holson R.R. Interactive effects of prenatal cocaine and nicotine exposure on maternal toxicity, postnatal development and behavior in the rat. Mol. Neurobiol. 11:1995;121-143.
96. Stahle L. Do autoreceptors mediate dopamine agonist-induced yawning and suppression of exploration? A critical review. Psychopharmacology. 106:1992;1-13.
97. Stahle L., Ungerstedt U. Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by a low dose of apomorphine: implications for the identity of dopamine receptors. Pharmacol. Biochem. Behav. 25:1986;473-480.
98. Stahle L., Ungerstedt U. Yawning and suppression of exploration induced by dopamine agonists: no relation to extracellular striatal levels of dopamine. Pharmacol. Biochem. Behav. 35:1990;201-209.
99. Stanwood G.D., McElligot S., Lu L., McGonigle P. Ontogeny of dopamine D3 receptors in the nucleus accumbens of the rat. Neurosci. Lett. 223:1997;13-16.
100. Svensson K., Carlsson A., Ruff R.M., Kling-Petersen T., Waters N. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur. J. Pharmacol. 262:1994;235-243.
101. Svensson K., Johansson A.M., Magnusson T., Carlsson A. (-) and (+)-UH 232: central stimulants acting as preferential dopamine receptor antagonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 3:1986;245-249.
102. Szechtman H. Effects of pretreatment with naloxone on behaviors induced by a small dose of apomorphine. Pharmacol. Biochem. Behav. 24:1986;1779-1783.
103. Tabachnick B.G., Fidell L.S. Using Multivariate Statistics. 4th ed. 2001;391-429 Allyn and Bacon, Boston, MA.
104. Tarazi F.I., Baldessarini R.J. Comparative postnatal development of D-1, D-2 and D-4 receptors in rat forebrain. Int. J. Dev. Neurosci. 18:2000;29-37.
105. Tarazi F.I., Tomasini E.C., Baldessarini R.J. Postnatal development of D4-like receptors in rat forebrain regions: comparison with D2-like receptors. Brain Res. Dev. Brain Res. 110:1998;227-233.
106. Tarazi F.I., Tomasini E.C., Baldessarini R.J. Postnatal development of D-1-like receptors in rat cortical and striatolimbic brain regions: an autoradiographic study. Dev. Neurosci. 21:1999;43-49.
107. Thorne L., Ashmeade T.E., Storey V.J., Routledge C., Reavill C. Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors. Neuropharmacology. 36:1997;787-792.
108. Tiberi M.M., Jarvie K.R., Silvia C., Falardeau P., Gingrich J.A., Godinot N., Bertrand L., Yang-Feng T.L., Fremeau R.T. Jr., Caron M.G. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc. Natl. Acad. Sci. 88:1991;7491-7495.
109. Undie A.S., Friedman E. Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics. Psychopharmacology (Berl.). 96:1988;311-316.
110. van Hartesveldt C., Meyer M.E., Potter T.J. Ontogeny of biphasic locomotor effects of quinpirole. Pharmacol. Biochem. Behav. 48:1994;781-786.
111. Wachtel S.R., Brooderson R.J., White F.J. Parametric and pharmacological analyses of the enhanced grooming response elicited by the D1 dopamine receptor. Psychopharmacology. 109:1992;41-48.
112. Waddington J.L., Daly S.A., Downes R.P., Deveney A.M., McCauley P.G., O'Boyle K.M. Behavioural pharmacology of 'D-1 like' dopamine receptors: further subtyping, neuropharmacological probes and interactions with 'D-2-like' receptors. Prog. Neuro-Psychopharmacol. 19:1995;811-831.
113. Wang L., Pitts D.K. Ontogeny of nigrostriatal dopamine neuron autoreceptors: iontophoretic studies. J. Pharmacol. Exp. Ther. 272:1995;164-176.
114. Waszczak B.L., Martin L.P., Finlay H.E., Zahr N., Stellar J.R. Effects of individual and concurrent stimulation of striatal D-1 and D-2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia. J. Pharmacol. Exp. Ther. 300:2002;850-861.
115. Waters N., Svensson K., Haadsma-Svensson S.R., Smith M.W., Carlsson A. The dopamine D-3 receptor: a postsynaptic receptor inhibitory on rat locomotor behavior. J. Neural Transm. 94:1993;11-19.
116. White F.J., Bednarz L.M., Wachtel S.R., Hjorth S., Brooderson R.J. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors? Pharmacol. Biochem. Behav. 30:1988;189-193.
117. Zuch C.L., Cory-Slechta D.A. Stimulus properties of 7-OD-DPAT versus auto- and postsynaptic receptor-specific doses of quinpirole. Pharmacol. Biochem. Behav. 68:2001;469-479.